Mudasir Rashid

Dr. Mudasir Rashid

Howard University Hospital, Washington D.C., USA
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2020 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
ASAsmita Sharda
Asmita Sharda
MRMudasir Rashid
Mudasir Rashid
SSSanket Girish Shah
Sanket Girish Shah
ASAjit Kumar Sharma
Ajit Kumar Sharma
SSSaurav Raj Singh
Saurav Raj Singh
SGSanjay Gupta
Sanjay Gupta
Background: Poor-responsiveness of tumors to radiotherapy is a major clinical problem. Owing to the dynamic nature of the epigenome, the identification and targeting of potential epigenetic modifiers may be helpful to curb radio-resistance. This requires a detailed exploration of the epigenetic changes that occur during the acquirement of radio-resistance. Such an understanding can be applied for effective utilization of treatment adjuncts to enhance the efficacy of radiotherapy and reduce the incidence of tumor recurrence. Results: This study explored the epigenetic alterations that occur during the acquirement of radio-resistance. Sequential irradiation of MCF7 breast cancer cell line up to 20 Gy generated a radio-resistant model. Micrococcal nuclease digestion demonstrated the presence of compact chromatin architecture coupled with decreased levels of histone PTMs H3K9ac, H3K27 ac, and H3S10pK14ac in the G0/G1 and mitotic cell cycle phases of the radio-resistant cells. Further investigation revealed that the radio-resistant population possessed high HDAC and low HAT activity, thus making them suitable candidates for HDAC inhibitor–based radio-sensitization. Treatment of radio-resistant cells with HDAC inhibitor valproic acid led to the retention of γH2AX and decreased H3S10p after irradiation. Additionally, an analysis of 38 human patient samples obtained from 8 different tumor types showed variable tumor HDAC activity, thus demonstrating inter-tumoral epigenetic heterogeneity in a patient population. Conclusion: The study revealed that an imbalance of HAT and HDAC activities led to the loss of site-specific histone acetylation and chromatin compaction as breast cancer cells acquired radio-resistance. Due to variation in the tumor HDAC activity among patients, our report suggests performing a prior assessment of the tumor epigenome to maximize the benefit of HDAC inhibitor–based radio-sensitization. Graphical

3 August 2020 in Epigenetics & Chromatin
Verified
Journal Article
Open access
PDF file
SSSanket G. Shah
Sanket G. Shah
TMTushar Mandloi
Tushar Mandloi
PKPooja Kunte
Pooja Kunte
ANAbhiram Natu
Abhiram Natu
MRMudasir Rashid
Mudasir Rashid
SGSanjay Gupta
Sanjay Gupta
Background: Epigenetics research is progressing in basic, pre-clinical and clinical studies using various model systems. Hence, updating the knowledge and integration of biological data emerging from in silico, in vitro and in vivo studies for different epigenetic factors is essential. Moreover, new drugs are being discovered which target various epigenetic proteins, tested in pre-clinical studies, clinical trials and approved by the FDA. It brings distinct challenges as well as opportunities to update the existingHIstomedatabase for implementing and applying enormous data for biomedical research.Results: HISTome2focuses on the sub-classification of histone proteins as variants and isoforms, post-translational modifications (PTMs) and modifying enzymes for humans (Homo sapiens), rat (Rattus norvegicus) and mouse (Mus musculus) on one interface for integrative analysis. It contains 232, 267 and 350 entries for histone proteins (non-canonical/variants and canonical/isoforms), PTMs and modifying enzymes respectively for human, rat, and mouse. Around 200 EpiDrugs for various classes of epigenetic modifiers, their clinical trial status, and pharmacological relevance have been provided inHISTome2. The additional features like ‘Clustal omega’ for multiple sequence alignment, link to ‘FireBrowse’ to visualize TCGA expression data and ‘TargetScanHuman’ for miRNA targets have been included in the database.Conclusion: The information for multiple organisms and EpiDrugs on a common platform will accelerate the understanding and future development of drugs. Overall,HISTome2 has significantly increased the extent and diversity of its content which will serve as a ‘knowledge Infobase’ for biologists, pharmacologists, and clinicians.HISTome2: The HISTone Infobaseis freely available onhttp://www.actrec.gov.in/histome2/.

23 August 2019 in Cell and Tissue Banking
Verified
Journal Article
Closed access
PDF file
SSSanket G. Shah
Sanket G. Shah
MRMudasir Rashid
Mudasir Rashid
TVTripti Verma
Tripti Verma
MLMadan Ludbe
Madan Ludbe
BKBharat Khade
Bharat Khade
SGSanjay Gupta
Sanjay Gupta

14 February 2020 in World Journal of Gastroenterology
Verified
Journal Article
Open access
RARamchandra V Amnekar
Ramchandra V Amnekar
SKShafqat A Khan
Shafqat A Khan
MRMudasir Rashid
Mudasir Rashid
BKBharat Khade
Bharat Khade
RTRahul Thorat
Rahul Thorat
SGSanjay Gupta
Sanjay Gupta
The prognosis of gastric cancer continues to remain poor, and epigenetic drugs like histone deacetylase inhibitors (HDACi) have been envisaged as potential therapeutic agents. Nevertheless, clinical trials are facing issues with toxicity and efficacy against solid tumors, which may be partly due to the lack of patient stratification for effective treatments. To study the need of patient stratification before HDACi treatment, and the efficacy of pre-treatment of HDACi as a chemotherapeutic drug sensitizer. The expression activity of class 1 HDACs and histone acetylation was examined in human gastric cancer cells and tissues. The potential combinatorial regime of HDACi and chemotherapy drugs was defined on the basis of observed drug binding assays, chromatin remodeling and cell death. In the present study, the data suggest that the differential increase in HDAC activity and the expression of class 1 HDACs are associated with hypo-acetylation of histone proteins in tumors compared to normal adjacent mucosa tissue samples of gastric cancer. The data highlights for the first time that pre-treatment of HDACi results in an increased amount of DNA-bound drugs associated with enhanced histone acetylation, chromatin relaxation and cell cycle arrest. Fraction-affected plots and combination index-based analysis show that pre-HDACi chemo drug combinatorial regimes, including valproic acid with cisplatin or oxaliplatin and trichostatin A with epirubicin, exhibit synergism with maximum cytotoxic potential due to higher cell death at low combined doses in gastric cancer cell lines. Expression or activity of class 1 HDACs among gastric cancer patients present an effective approach for patient stratification. Furthermore, HDACi therapy in pre-treatment regimes is more effective with chemotherapy drugs, and may aid in predicting individual patient prognosis.

1 April 2021 in Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms
Verified
Journal Article
Closed access
MRMudasir Rashid
Mudasir Rashid
SSSanket Girish Shah
Sanket Girish Shah
TVTripti Verma
Tripti Verma
NCNazia Chaudhary
Nazia Chaudhary
SRSukanya Rauniyar
Sukanya Rauniyar
SGSanjay Gupta
Sanjay Gupta

12 August 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
MRMudasir Rashid
Mudasir Rashid
Hassan BrimHassan Brim
Hassan Brim
Hassan AshktorabHassan Ashktorab
Hassan Ashktorab
Intensive screening for better and safer medications to treat diseases such as cancer and inflammatory diseases continue, and some phytochemicals have been discovered to have anti-cancer and many therapeutical activities. Among the traditionally used spices, Crocus sativus (saffron) and its principal bioactive constituents have anti-inflammatory, antioxidant, and chemopreventive properties against multiple malignancies. Early reports have shown that the epigenetic profiles of healthy and tumor cells vary significantly in the context of different epigenetic factors. Multiple components, such as carotenoids as bioactive dietary phytochemicals, can directly or indirectly regulate epigenetic factors and alter gene expression profiles. Previous reports have shown the interaction between active saffron compounds with linker histone H1. Other reports have shown that high concentrations of saffron bind to the minor groove of calf thymus DNA, resulting in specific structural changes from B- to C-form of DNA. Moreover, the interaction of crocin G-quadruplex was reported. A recent in silico study has shown that residues of SIRT1 interact with saffron bio-active compounds and might enhance SIRT1 activation. Other reports have shown that the treatment of Saffron bio-active compounds increases γH2AX, decreases HDAC1 and phosphorylated histone H3 (p-H3). However, the question that still remains to be addressed how saffron triggers various epigenetic changes? Therefore, this review discusses the literature published till 2022 regarding saffron as dietary components and its impact on epigenetic mechanisms. Novel bioactive compounds such as saffron components that lead to epigenetic alterations might be a valuable strategy as an adjuvant therapeutic drug.
1